Eton Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Eton Pharmaceuticals has a total shareholder equity of $15.5M and total debt of $5.0M, which brings its debt-to-equity ratio to 32.4%. Its total assets and total liabilities are $30.8M and $15.3M respectively. Eton Pharmaceuticals's EBIT is $542.0K making its interest coverage ratio -0.9. It has cash and short-term investments of $16.7M.
Key information
32.4%
Debt to equity ratio
US$5.02m
Debt
| Interest coverage ratio | -0.9x |
| Cash | US$16.66m |
| Equity | US$15.49m |
| Total liabilities | US$15.30m |
| Total assets | US$30.79m |
Recent financial health updates
Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Despite Losing Money
Sep 30
Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?
Jun 29Is Eton Pharmaceuticals (NASDAQ:ETON) Using Debt In A Risky Way?
Dec 22Eton Pharmaceuticals (NASDAQ:ETON) Is Using Debt Safely
Oct 14Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?
Apr 05Recent updates
Subdued Growth No Barrier To Eton Pharmaceuticals, Inc. (NASDAQ:ETON) With Shares Advancing 40%
Jan 09The Consensus EPS Estimates For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Just Fell A Lot
Dec 13Eton Pharmaceuticals' (NASDAQ:ETON) Earnings May Just Be The Starting Point
Nov 16Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Despite Losing Money
Sep 30Not Many Are Piling Into Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Yet As It Plummets 26%
Jul 25Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?
Jun 29Is Eton Pharmaceuticals (NASDAQ:ETON) Using Debt In A Risky Way?
Dec 22Eton Pharmaceuticals acquires FDA-approved rare disease product betaine anhydrous
Sep 13Eton Pharmaceuticals: An Evolving 'Sum Of The Parts' Story
Aug 14Eton Pharma jumps 20% on FDA approval of seizure therapy
Jul 18Broker Revenue Forecasts For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Are Surging Higher
Apr 15Eton Pharmaceuticals (NASDAQ:ETON) Is Using Debt Safely
Oct 14Another Look At Eton Pharmaceuticals
Sep 03What Does The Future Hold For Eton Pharmaceuticals, Inc. (NASDAQ:ETON)? These Analysts Have Been Cutting Their Estimates
Aug 18Eton Pharma wins FDA approval for Rezipres
Jun 15FDA declines to approve Eton Pharmaceuticals' methanol poisoning treatment
May 28Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Is About To Turn The Corner
May 15Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?
Apr 05Could The Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Ownership Structure Tell Us Something Useful?
Mar 01Eton Pharma buys Canadian rights for Alkindi Sprinkle
Jan 14Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Shift From Loss To Profit
Jan 07
FDA accepts Eton application for Topiramate for partial seizures
Dec 17Eton Pharmaceuticals announces availability of ALKINDI SPRINKLE in U.S.
Nov 24Financial Position Analysis
Short Term Liabilities: ETON's short term assets ($24.3M) exceed its short term liabilities ($15.3M).
Long Term Liabilities: ETON has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: ETON has more cash than its total debt.
Reducing Debt: ETON's debt to equity ratio has increased from 0% to 32.4% over the past 5 years.
Debt Coverage: ETON's debt is well covered by operating cash flow (117.3%).
Interest Coverage: ETON earns more interest than it pays, so coverage of interest payments is not a concern.